The MEA biochips market size surpassed USD 460 million in 2025 and is predicted to reach around USD 1329.86 million by 2035, registering a CAGR of 11.2% from 2026 to 2035. The market growth is driven by increasing healthcare spending and a stronger focus on patient safety standards.

MEA Biochips Market Statical Scope

Countries such as Saudi Arabia and the UAE are investing in advanced laboratory technologies and expanding blood screening capabilities to support healthcare modernization efforts. Growth in hospital infrastructure, medical tourism, and demand for reliable transfusion diagnostics is contributing to wider adoption of immunohematology systems.

The increasing cases of inherited blood disorders and other chronic diseases demand blood transfusion services and specialized diagnostic reagents. Healthcare institutions are prioritizing laboratory efficiency and regulatory compliance across the region.

MEA Biochips Market, By Product, 2025 (%)

• Analyzers - Analyzers hold a significant portion, with a share of 38%, due to increasing laboratory automation. Hospitals and blood banks are adopting automated immunohematology analyzers for efficient and accurate blood screening to improve turnaround time and minimize manual errors.
• Reagents - Reagents dominate the segment, with a share of 62%, driven by their consistent demand for blood grouping, antibody screening and compatibility testing. The reagents are used in routine immunohematology testing procedures.

MEA Biochips Market, By Technology, 2025 (%)

• Gel Cards - Gel Cards follow, with a share of 28%, supported by their reliable test interpretation and standardized laboratory procedures. Hospitals and blood banks continue adopting gel card systems in routine immunohematology testing to improve operational consistency and support accurate compatibility testing.
• Erythrocyte -Magnetized Technology - Erythrocyte-Magnetized Technology follows, with a share of 20%, driven by improving laboratory infrastructure and growing focus on transfusion safety standards. Hospitals and diagnostic centres are implementing automation to improve testing efficiency and support modernization of blood screening.
• PCR - PCR accounts for a significant share, with a share of 30%, supported by its high accuracy and increasing use in molecular-level blood diagnostics. Laboratories are implementing PCR based testing to improve antigen identification accuracy and support complex compatibility analysis.

MEA Biochips Market, By End Use Outlook, 2025 (%)

• Hospitals - Hospitals lead the segment, with a share of 50%, driven by growing healthcare infrastructure and increasing demand for transfusion services. Healthcare providers are investing in advanced laboratory systems to offer specialized services to patients
• Diagnostic Laboratories - Diagnostic Laboratories follow, with a share of 30%, supported by increasing demand for specialized testing services and laboratory modernization. The expanding diagnostic infrastructure and increasing outsourcing of testing services further support the growth of the segment in the market.

Segments Covered in the Report

By Product

• Analyzers
• Reagents

By Technology

• Biochips
• Gel Cards
• Microplates
• PCR
• Erythrocyte-Magnetized Technology

By End Use Outlook

• Hospitals
• Diagnostic Laboratories
• Blood Banks